Article

MorphoSys and Novartis Form Strategic Alliance

MorphoSys AG (Munich, Germany) and Novartis (East Hanover, NJ) have formed a comprehensive strategic alliance for the discovery and development of biopharmaceuticals.

MorphoSys AG (Munich, Germany) and Novartis (East Hanover, NJ) have formed a comprehensive strategic alliance for the discovery and development of biopharmaceuticals. The deal is aimed at establishing a pipeline of innovative drugs, and combines MorphoSys’ and Novartis’ research and development capabilities.

According to this agreement, Novartis becomes MorphoSys’s preferred collaborator for HuCAL-based drug discovery, allowing MorphoSys to progress to the next stage of its corporate development, which involves a greater focus on drug discovery and development.

Total payments under the agreement, including committed payments and milestones, could exceed $1 billion, assuming the collaboration successfully runs its maximum term.

MorphoSys releaseNovartis web site

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet
© 2025 MJH Life Sciences

All rights reserved.